DK1470818T3 - Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS - Google Patents

Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS

Info

Publication number
DK1470818T3
DK1470818T3 DK03291024T DK03291024T DK1470818T3 DK 1470818 T3 DK1470818 T3 DK 1470818T3 DK 03291024 T DK03291024 T DK 03291024T DK 03291024 T DK03291024 T DK 03291024T DK 1470818 T3 DK1470818 T3 DK 1470818T3
Authority
DK
Denmark
Prior art keywords
hours
neuroprotective
pns
cns
phenothiazine derivatives
Prior art date
Application number
DK03291024T
Other languages
English (en)
Inventor
Aline Appert-Colin
Noelle Callizot
Original Assignee
Neuro3D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro3D filed Critical Neuro3D
Application granted granted Critical
Publication of DK1470818T3 publication Critical patent/DK1470818T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK03291024T 2003-04-25 2003-04-25 Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS DK1470818T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291024A EP1470818B1 (en) 2003-04-25 2003-04-25 Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns

Publications (1)

Publication Number Publication Date
DK1470818T3 true DK1470818T3 (da) 2006-11-20

Family

ID=32946961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03291024T DK1470818T3 (da) 2003-04-25 2003-04-25 Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS

Country Status (9)

Country Link
US (1) US20060276460A1 (da)
EP (1) EP1470818B1 (da)
AT (1) ATE333881T1 (da)
DE (1) DE60307049T2 (da)
DK (1) DK1470818T3 (da)
ES (1) ES2272911T3 (da)
HK (1) HK1066741A1 (da)
PT (1) PT1470818E (da)
WO (1) WO2004096231A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2911143A1 (fr) * 2007-01-05 2008-07-11 Servier Lab Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives.
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
WO2013043744A2 (en) * 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
JP2017507977A (ja) * 2014-03-10 2017-03-23 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ 痙縮を治療するためのピペラジンフェノチアジン誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
US3320245A (en) * 1964-08-21 1967-05-16 American Home Prod Derivatives of phenothiazine-10-glyoxylic acids and intermediates in the preparationthereof
US3320249A (en) * 1965-07-09 1967-05-16 Olin Mathieson Adamantyl derivatives of phenothiazines
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
AU708682B2 (en) * 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
US6514686B2 (en) * 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
WO1999007356A1 (en) * 1997-08-11 1999-02-18 University Of South Florida Research Foundation, Inc. Nicotine antagonists for neuropsychiatric disorders
FR2784678B1 (fr) * 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
EE200100302A (et) * 1998-12-02 2002-08-15 Pfizer Products Inc. Meetodid ja kompositsioonid p53 perekonna valgu konformatsioonilise stabiilsuse taastamiseks
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
CA2310205A1 (en) * 2000-05-29 2001-11-29 Dalhousie University Unknown
CA2418720A1 (en) * 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US20030229082A1 (en) * 2002-01-16 2003-12-11 The Regents Of The University Of California Inhibition of RNA function
FR2835254B1 (fr) * 2002-01-25 2006-04-07 Sod Conseils Rech Applic Derives de thiazoles dans le traitement de maladies neurologiques

Also Published As

Publication number Publication date
EP1470818B1 (en) 2006-07-26
ES2272911T3 (es) 2007-05-01
US20060276460A1 (en) 2006-12-07
PT1470818E (pt) 2006-11-30
WO2004096231A3 (en) 2005-03-24
EP1470818A1 (en) 2004-10-27
DE60307049D1 (de) 2006-09-07
HK1066741A1 (en) 2005-04-01
WO2004096231A2 (en) 2004-11-11
DE60307049T2 (de) 2007-02-08
ATE333881T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
NO991951L (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
Calkins et al. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage
NO955219D0 (no) Nye kjemiske forbindelser med PDE-IV-inhiberende aktivitet
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
DE502004006219D1 (de) Neue 8-(piperazin-1-yl)- und 8-( 1,4 diazepan-1-yl)-xanthine, deren herstellung und deren verwendung als arzneimittel
NO20054726L (no) 2, 4-di(fenylamino)pyrimidiner anvendelige ved behandling av neoplastiske sykdommer, inflammasjons- og immunsystemforstyrrelser
DE3686927D1 (de) Neovaskularisierungsinhibitoren und deren herstellung.
WO2004041258A8 (fr) Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
WO2005046570A3 (en) Human stem cell materials and methods
UY29077A1 (es) Amidas sustituidas de ácido tienopirrolcarboxílico, amidas del ácido pirrolotiazolcarboxílico y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon)
Zhu et al. Luteolin reduces primary hippocampal neurons death induced by neuroinflammation
Pei et al. Sevoflurane suppresses microglial M2 polarization
DK1470818T3 (da) Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS
WO2006044842A3 (en) Pancreatic islet beta-cell-like macrophages and methods to produce them
ITMI20022724A1 (it) Sali cristallini del cefdinir.
Swayne et al. Ion channels in postnatal neurogenesis: potential targets for brain repair
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
ATE420101T1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler
NO933960L (no) Interleukinreseptor-maalsoekende molekyler for behandling av inflam matorisk artritis
WO2020197059A3 (ko) 엽산, 엽산 유도체, 또는 엽산 저해제를 이용한 줄기세포의 연골세포로의 분화 유도 방법
DE59904875D1 (de) Substituierte phenyl-alkenoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikamente oder diagnostika sowie sie enthaltende medikamente
HRP940210A2 (en) New imidazoloquinoxalinones their production and use
ATE181832T1 (de) Pyrido-pyrimidindione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
Tsiang et al. Inhibition of rabies virus infection in cultured rat cortical neurons by an N-methyl-D-aspartate noncompetitive antagonist, MK-801